Source: Siyu MedTech; Editor: Sophia

Global Surgical Robotics Conference Partner Solicitation ｜  Award Application

Surgical Robot Training ｜Pre-registration for Medical Aesthetics Events

July 23, 2024Boston Scientific Corporation (NYSE: BSX) announced its latest Q2 financial report,Reported net sales of $4.12 billion (approximately 29.911 billion RMB), an increase of 14.5% compared to the same period last year on a reported basis.

Reported net sales were $4.12 billion, an increase of 14.5% compared to the same period last year;

This figure was $261 million in 2023, or $0.18 per share, with adjusted earnings per share of $0.53.

• United States: Net sales reported a 16.9% increase;

• Europe, Middle East and Africa (EMEA): Net sales reported a 13.7% increase;

• Asia-Pacific (APAC): Net sales reported a 7.0% increase;

• Latin America and Canada (LACA):Net Sales Report Growth15.3%；

• Emerging Markets: Net Sales Report Growth of 14.8%.

By Business Category

• Neuromodulation business sales reached $282 million, increasing by 15.5% year-over-year; the launch of competitive products resulted in low single-digit growth for brain stimulation products, while pain stimulation products achieved strong double-digit growth; to date, more than 30,000 patients have been treated with the Intracept system.

• UrologySales revenue reached $5.25 billion, representing an 8.2% increase year-over-year; Stone Management and Prosthetic Urology achieved double-digit growth; International growth of 14% was driven by laser therapy and Rezum.
• Endoscopy grew 7.1% to $678 million, driven by strong growth in AXIOS™ and intraluminal surgeries.

Interventional cardiology sales of $665 million, organic growth of 9%;

• WATCHMAN business sales reached $379 million, with organic growth of 20%;

Cardiac Rhythm Management sales of $576 million, organic growth of 3%;

Electrophysiology business sales reached $428 million, with organic growth of 125%.

# Major Developments in the Second Quarter

• July 8, 2024Boston Scientific CorporationAnnounced under itsFARAPULSE™Series of Pulsed Electric Field Ablation Products, including FARAWAVE™ Single-Use Cardiac Pulsed Field Ablation Catheter, FARASTAR™ Cardiac Pulsed Field Ablation System, have received approval from the National Medical Products Administration (NMPA).。

  
  

  Boston Scientific Becomes the First Company in the World to Simultaneously Receive FDA/CE/NMPA Approval for a Pulsed Field Ablation (PFA) System to Treat Atrial Fibrillation。

  Related Reading:Approved for Marketing and Launched in China! In-Depth Analysis of the World’s First Pulse Ablation System from Boston Scientific

• March 2024,Boston Scientific CorporationBoston Scientific Corporation Announces FDA Approval of AGENT™ Drug-Coated Balloon Catheter (DCB) for the Treatment of In-Stent Restenosis (ISR) in Coronary Artery Disease Patients
  In June 2024, the AGENT balloon catheter received approval from the National Medical Products Administration (NMPA).
  Related Reading:Approved for Marketing! Boston Scientific's New Generation Drug-Coated Balloon

• June 19, 2024Boston Scientific CorporationBoston Scientific Corporation (NYSE: BSX) has signed the final agreement for the acquisition of Silk Road Medical, Inc. (Nasdaq: SILK).
  Silk Road Medical, Inc. is a medical device company that has developed an innovative platform product to provide stroke prevention for carotid artery patients through minimally invasive surgery — Transcarotid Artery Revascularization (TCAR). The acquisition price is $27.5 per share, with an equity value of approximately $1.16 billion.
  Related Reading:$8.4 Billion! Boston Scientific Announces Acquisition of Transcarotid Artery Revascularization Company
• At the 2024 American Pain and Neuroscience Society Conference,PublishFinishedResults of Three Follow-up Studies on Patients Treated with the Intracept™ Bone Marrow Nerve Ablation System。
  The study showed that vertebrogenic pain was significantly improved, with nearly one-third of patients being 100% pain-free after 5 treatments.

• The following clinical data were presented at Heart Rhythm 2024:

• Sub-analysis Results of the Key ADVENT Clinical Trial for the FARAPULSE PFA System,Patients treated with the FARAPULSE PFA System showed a greater reduction in arrhythmia burden compared to thermal ablation.

• Global FARADISE Registry Acute Results Show Favorable Outcomes in More Than 1,100 Patients Treated With The FARAPULSE PFA System at 30 Days, With No Reports of Death, Coronary Spasm, Persistent Phrenic Nerve Palsy, Atrial Esophageal Fistula or Pulmonary Vein Stenosis.

• Modular CRM (mCRM™) System 5 Achieves Positive Results in Ongoing Pivotal MODULAR ATP Clinical Trial, achieving all pre-specified six-month safety and efficacy endpoints.
  This is the first modular Cardiac Rhythm Management (mCRM) system, comprising the EBLEM™ Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker.